Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Global Tuberculosis Report 2020 - Reflections on the Global TB burden, treatment and prevention efforts.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2021
Same author

Evidences for lipid involvement in SARS-CoV-2 cytopathogenesis.

Cell death & disease·2021
Same author

Addressing challenges to rolling out COVID-19 vaccines in African countries.

The Lancet. Global health·2021
Same author

Zoonotic Tuberculosis - The Changing Landscape.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2021
Same author

Accelerating development of new shorter TB treatment regimens in anticipation of a resurgence of multi-drug resistant TB due to the COVID-19 pandemic.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2021
Same author

Lethal zoonotic coronavirus infections of humans - comparative phylogenetics, epidemiology, transmission, and clinical features of coronavirus disease 2019, The Middle East respiratory syndrome and severe acute respiratory syndrome.

Current opinion in pulmonary medicine·2021
Same journal

NET-inducing ability of Cutibacterium acnes clinical isolates is associated with pathogenicity in acne vulgaris.

The Journal of infectious diseases·2026
Same journal

Optimizing the Use of Proviral DNA HIV Drug Resistance Testing: Clinical Applications and Cautions.

The Journal of infectious diseases·2026
Same journal

Monitoring HLA-A2-restricted T cell responses and BCLA-specific serostatus during human latent Toxoplasma gondii infection suggests the implication of CD8+ T cells in parasite containment.

The Journal of infectious diseases·2026
Same journal

Cryptosporidiosis in Ptients with Inborn Errors of Immunity: Retrospective cohort study of the French National Reference Center (CEREDIH).

The Journal of infectious diseases·2026
Same journal

Type 3 fimbrial regulation underpins anti-MrkA immunotherapeutic efficacy in experimental Klebsiella pneumoniae infection.

The Journal of infectious diseases·2026
Same journal

Rationalising heterogeneity in Staphylococcus aureus bacteraemia: current progress and future goals.

The Journal of infectious diseases·2026
See all related articles

Related Experiment Video

Updated: May 23, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

Adjunct immunotherapies for tuberculosis.

Michael Uhlin1, Jan Andersson, Alimuddin Zumla

  • 1Center for Allogeneic Stem Cell Transplantation, Department of Laboratory Medicine, University College London Medical School, United Kingdom.

The Journal of Infectious Diseases
|March 30, 2012
PubMed
Summary
This summary is machine-generated.

Adjunct immunotherapy offers a promising strategy to combat multidrug-resistant tuberculosis. These immune-boosting treatments may improve outcomes and shorten treatment duration for various forms of tuberculosis.

More Related Videos

Adjuvant Activity of Mycobacterium paratuberculosis in Enhancing the Immunogenicity of Autoantigens During Experimental Autoimmune Encephalomyelitis
06:57

Adjuvant Activity of Mycobacterium paratuberculosis in Enhancing the Immunogenicity of Autoantigens During Experimental Autoimmune Encephalomyelitis

Published on: May 12, 2023

Related Experiment Videos

Last Updated: May 23, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

Adjuvant Activity of Mycobacterium paratuberculosis in Enhancing the Immunogenicity of Autoantigens During Experimental Autoimmune Encephalomyelitis
06:57

Adjuvant Activity of Mycobacterium paratuberculosis in Enhancing the Immunogenicity of Autoantigens During Experimental Autoimmune Encephalomyelitis

Published on: May 12, 2023

Area of Science:

  • Immunology
  • Infectious Diseases
  • Pulmonology

Background:

  • Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) present significant global health challenges.
  • Current treatment regimens for MDR-TB and XDR-TB are lengthy, expensive, toxic, and often yield poor outcomes.
  • The host immune system plays a crucial role in controlling Mycobacterium tuberculosis infection, highlighting the potential for immunotherapeutic interventions.

Purpose of the Study:

  • To provide a critical overview of current adjunct immunotherapies for active tuberculosis.
  • To explore the potential of immunotherapies in improving treatment success rates for MDR-TB and XDR-TB.
  • To discuss the various stages of development for novel immunotherapeutic approaches.

Main Methods:

  • Review of current literature on adjunct immunotherapies for tuberculosis.
  • Analysis of the role of host immune responses in tuberculosis containment and cure.
  • Evaluation of different immunotherapeutic strategies, including cytokine and cell-based therapies.

Main Results:

  • Adjunct immunotherapy, including cytokine treatments like interleukin-2, interferon-γ, and interleukin-7, shows potential to enhance treatment efficacy.
  • Immunotherapy may improve treatment success rates for MDR-TB, shorten treatment for drug-sensitive TB, and bolster host immunity to prevent recurrence.
  • While various immunotherapies are available, many require further clinical evaluation.

Conclusions:

  • Adjunct immunotherapy represents a promising avenue for improving tuberculosis treatment outcomes, particularly for drug-resistant strains.
  • Modulating host immune responses can be beneficial in managing tuberculosis, especially in cases with inflammation-induced tissue damage.
  • Further research and clinical trials are essential to fully evaluate the safety and efficacy of these emerging immunotherapies.